Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$2.6 million.

  • UroGen Pharma's Net Cash Flow rose 9725.76% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 68979.04%. This contributed to the annual value of $77.2 million for FY2024, which is 9504.07% up from last year.
  • Per UroGen Pharma's latest filing, its Net Cash Flow stood at -$2.6 million for Q3 2025, which was up 9725.76% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Net Cash Flow ranged from a high of $99.2 million in Q3 2023 and a low of -$94.8 million during Q3 2024
  • Moreover, its 5-year median value for Net Cash Flow was -$11.0 million (2021), whereas its average is $2.0 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 55135.27% in 2022, then surged by 63948.57% in 2024.
  • UroGen Pharma's Net Cash Flow (Quarter) stood at -$11.0 million in 2021, then soared by 343.45% to $26.7 million in 2022, then tumbled by 190.93% to -$24.3 million in 2023, then skyrocketed by 293.72% to $47.1 million in 2024, then tumbled by 105.52% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$11.1 million for Q2 2025, and -$68.0 million during Q1 2025.